Who are Merck and Company's Varivax's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): MMR vaccine (Priorix), Measles, Mumps, Rubella vaccination, Measles vaccine, Mumps vaccine, Live (MV), Rotavirus vaccine, Rotarix TM.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/merck-and-company-s-varivax.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Merck and Company's Varivax — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Merck and Company's Varivax (Merck and Company's Varivax) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated vaccine. Area: Immunology / Infectious Disease.

phase 3 Live attenuated vaccine Varicella-zoster virus (VZV) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Merck and Company's Varivax (Merck and Company's Varivax) — GlaxoSmithKline. Varivax is a live attenuated varicella-zoster virus vaccine that stimulates immune response to prevent chickenpox infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Merck and Company's Varivax TARGET	Merck and Company's Varivax	GlaxoSmithKline	phase 3	Live attenuated vaccine	Varicella-zoster virus (VZV)
MMR vaccine (Priorix)	MMR vaccine (Priorix)	GlaxoSmithKline	marketed	Live attenuated vaccine
Measles, Mumps, Rubella vaccination	Measles, Mumps, Rubella vaccination	N.M. Wulffraat	marketed	Live attenuated vaccine
Measles vaccine	Measles vaccine	Bandim Health Project	marketed	Live attenuated vaccine	Measles virus surface glycoproteins (H and F proteins)
Mumps vaccine, Live (MV)	Mumps vaccine, Live (MV)	Sinovac Biotech Co., Ltd	marketed	Live attenuated vaccine
Rotavirus vaccine	Rotavirus vaccine	PATH	marketed	Live attenuated vaccine
Rotarix TM	Rotarix TM	GlaxoSmithKline	marketed	Live attenuated vaccine	Rotavirus (RIX4414 strain)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated vaccine class)

GlaxoSmithKline · 19 drugs in this class
Merck Sharp & Dohme LLC · 11 drugs in this class
Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
PATH · 5 drugs in this class
Sanofi · 5 drugs in this class
Bandim Health Project · 5 drugs in this class
Centers for Disease Control and Prevention · 3 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
Beijing Center for Disease Control and Prevention · 2 drugs in this class
Aga Khan University · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Merck and Company's Varivax — Competitive Intelligence Brief. https://druglandscape.com/ci/merck-and-company-s-varivax. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab